

Special Issue

Dual Diagnosis: A Clinical Perspective Regarding Symptoms and Treatments

Message from the Guest Editor

Dual diagnosis, also known as co-occurring disorders, refers to the simultaneous presence of a mental health disorder and a substance use disorder (SUD) within an individual. The concept of dual diagnosis acknowledges the bidirectional relationship between mental illness and substance use, where one disorder may contribute to the onset or worsening of the other. Common mental health conditions associated with dual diagnosis include depression, anxiety, bipolar disorder, and schizophrenia, alongside SUDs involving alcohol, opioids, or stimulants. This Special Issue aims to investigate the clinical aspects of dual diagnosis, the treatments available, and the proposal of interventions for these specific conditions, particularly focusing on pharmacological and clinical–pharmacological issues, such as the possibility of drug interactions with ongoing treatments or substances (polysubstance use), age-related characteristics, types of psychiatric disorders and related treatments, settings, and emerging “New Psychoactive Substances” (NPSs), which might be concomitantly abused.

Guest Editor

Dr. Stefania Chiappini

School of Medicine, UniCamillus International Medical School University, Via di S. Alessandro 8, 00131 Rome, Italy

Deadline for manuscript submissions

closed (31 August 2025)



Future Pharmacology

an Open Access Journal
by MDPI

Impact Factor 2.7



mdpi.com/si/217859

Future Pharmacology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
future-
pharmacology@mdpi.com

[mdpi.com/journal/
futurepharmacol](https://mdpi.com/journal/futurepharmacol)





Future Pharmacology

an Open Access Journal
by MDPI

Impact Factor 2.7



[mdpi.com/journal/
futurepharmacol](https://mdpi.com/journal/futurepharmacol)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Fabrizio Schifano
Psychopharmacology, Drug Misuse and Novel Psychoactive
Substances Research Unit, School of Life and Medical Sciences,
University of Hertfordshire, Hertfordshire AL10 9AB, UK

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid
by authors or their institutions.

High Visibility:

indexed within ESCI (Web of Science), EBSCO, and other
databases.

Journal Rank:

JCR - Q2 (Pharmacology and Pharmacy)